Q2 2026 Bayer AG Earnings Call Transcript
Key Points
- Bayer AG (BAYRY) reported a 3% increase in group sales to EUR24 billion in H1 2026, with core EPS up 3% to EUR3.66, meeting expectations.
- CropScience delivered strong performance with 5.5% sales growth and a significant EBITDA margin expansion to 31%, driven by higher-margin sales and disciplined execution.
- Pharma's new products Nubeqa and Karendia combined for 66% growth, offsetting declines in Xarelto and EYLEA, and the company is at an inflection point for growth.
- The U.S. Supreme Court ruling in Monsanto v. Durnell is a landmark victory for Bayer AG (BAYRY), providing regulatory clarity and strengthening its litigation containment strategy.
- The EUR3 billion equity investment from Apollo and successful $5 billion bond placement strengthen the balance sheet, with net financial debt guidance improved to EUR29-30 billion.
- Consumer Health posted 3.5% growth, with strong contributions from nutritionals and dermatology, and e-commerce continues to be a key growth driver.
- Free cash flow was negative EUR2.7 billion in H1 2026, worse than the prior year, due to EUR2.5 billion in litigation-related payouts.
- Pharma EBITDA margin declined to 23.7% in Q2 due to increased growth investments and pricing pressures, with Xarelto and EYLEA declining 42% and 33% respectively.
- Core crop protection sales declined 5% year-to-date due to generic pressure and portfolio pruning, with continued regulatory and pricing headwinds expected.
- The company faces ongoing litigation uncertainty, with the class settlement still pending final approval and potential opt-outs, and PCB indemnity cases ongoing.
- Consumer Health EBITDA margin is trailing prior year, impacted by foreign exchange headwinds and softer seasonal demand in allergy and cold categories.
- The transition to new soybean technologies in Latin America and the U.S. is expected to weigh on sales in the second half, with potential El Nino impacts on crop science.
Good afternoon and good morning, everyone. And welcome to our conference call to discuss Bayer's second quarter 2026 results.
Bill will begin by sharing his perspective on the key achievements of the past few weeks and our path forward. And we are delighted today to have Judith with us for her first quarterly earnings call. She will offer her initial perspectives and provides further insights into business performance and the outlook.
Following the prepared remarks, we will open the call for Q&A and our three divisional Presidents will join Bill and Judith then to address questions.
Before we get started, I would also like to encourage you to join our CropScience Field event on September the second in Iowa. If you have any questions regarding registration or logistics, please reach out to our investor relations team.
As always, please note the cautionary language in our safe harbor statement.
And with that, over to you.
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
